

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Lectade Plus Powder for Oral Solution

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

#### **Active substances:**

##### **Each Sachet A contains:**

|                                |        |
|--------------------------------|--------|
| Sodium chloride                | 4.59 g |
| Glycine                        | 3.01 g |
| Potassium dihydrogen phosphate | 1.36 g |
| Sodium acid citrate            | 1.80 g |
| Potassium citrate              | 3.24 g |
| Sodium citrate                 | 0.66 g |

##### **Each Sachet B contains:**

|                     |         |
|---------------------|---------|
| Glucose monohydrate | 62.69 g |
|---------------------|---------|

When reconstituted as recommended, each litre contains:

|           |          |
|-----------|----------|
| Glycine   | 20 mmol  |
| Sodium    | 50 mmol  |
| Potassium | 20 mmol  |
| Chloride  | 39 mmol  |
| Citrate   | 10 mmol  |
| Phosphate | 5 mmol   |
| Glucose   | 160 mmol |

#### **Excipient:**

| <b>Qualitative composition of excipients and other constituents</b> | <b>Quantitative composition if that information is essential for proper administration of the veterinary medicinal product</b> |
|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Sachet A:<br>Erythrosine (E 127)                                    | 0.005 g                                                                                                                        |

Sachet A: Pink powder  
Sachet B: White powder

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Calves.

### **3.2 Indications for use for each target species**

The veterinary medicinal product is indicated as an oral rehydration therapy for the treatment of diarrhoea in calves by reversing the process of dehydration, acidosis and loss of electrolytes associated with diarrhoea, whether caused by bacteria, viruses, cryptosporidia or inappropriate nutrition.

### **3.3 Contraindications**

None.

### **3.4 Special warnings**

In severe cases of dehydration some animals may require additional intravenous rehydration therapy. In such cases consult a veterinary surgeon.

### **3.5 Special precautions for use**

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Not applicable.

Special precautions for the protection of the environment:

Not applicable.

### **3.6 Adverse events**

Target species: Calves

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

Not applicable.

### **3.8 Interaction with other medicinal products and other forms of interaction**

None known.

The veterinary medicinal product has been shown to be compatible with oral antibiotics such as amoxicillin, ampicillin and oxytetracycline.

### **3.9 Administration routes and dosage**

Oral use.

The contents of sachets A and B should be added to 2 litres (approximately 3.5 pints) of fresh water, at a temperature of about 35°C.

Scouring calves

Immediately scour symptoms show, withdraw milk or milk replacer and offer 2 litres of solution twice daily for two days (four feeds). For the next four feeds offer 1 litre of the veterinary medicinal product solution added to 1 litre of milk or milk replacer. Thereafter feed as normal.

Duration of treatment

If the scouring is established or severe, thus causing serious dehydration, the solution should be fed three or four times daily. The veterinary medicinal product may be used on its own for a maximum of four days. Ensure that adequate colostrum is fed to all calves.

General recommendations

Keep feeding utensils clean. Any medicated water which is not consumed within 24 hours should be discarded.

The reconstituted product forms a pink solution.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

No adverse effects are to be expected from an accidental overdose.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Meat and offal: Zero days.

## **4. PHARMACOLOGICAL INFORMATION**

A glucose-glycine-electrolyte formulation which is effective in oral rehydration therapy. The underlying principles of this are:

1. Intestinal absorption of glucose and amino acids is an active process linked to the movement of sodium and water.
2. The linked absorption increases net fluid and electrolyte uptake and offsets fluid loss, so reversing the process of dehydration and diarrhoea;

3. When diarrhoea is caused by bacterial enterotoxins, the active transport of glucose and glycine is not impaired;

Diarrhoea may result in dehydration, hyponatraemia, hyperkalaemia and acidosis. Effective oral rehydration therapy will reverse the net secretion of fluid and electrolytes into the gut and promote net absorption of water, electrolytes and nutrients. The active ingredients of the veterinary medicinal product act in this way. Glucose and glycine are actively absorbed by a sodium-dependent mechanism, bringing about a net uptake of water. In addition, these ingredients also act as a source of energy (glucose) and amino acids (glycine). This increased content of energy and amino acid is particularly important for the calf when milk is withheld during the treatment regime.

Sodium and chloride ions from the salt form an essential part of the sodium dependent glucose and glycine transport mechanism, which promotes the absorption of water. Potassium dihydrogen phosphate provides potassium, phosphate and hydrogen ions, helping to restore electrolyte balance. Citrate ions further enhance water uptake from the gut and indirectly provide bicarbonate to correct the acidosis of dehydration and diarrhoea. The veterinary medicinal product has extra citrate ions which aid this process.

When made up with water as directed, the veterinary medicinal product forms an isotonic solution. This is beneficial, as a hypertonic solution would promote further water secretion into the gut, so exacerbating the diarrhoea.

#### **4.1 ATCvet code:**

QA07CQ02

### **5. PHARMACEUTICAL PARTICULARS**

#### **5.1 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

#### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years

Shelf life after reconstitution according to directions: 24 hours

#### **5.3 Special precautions for storage**

Store in a dry place.

Do not store above 25°C.

#### **5.4 Nature and composition of immediate packaging**

The veterinary medicinal product is presented in twinned laminated sachets of two sizes. The laminate consists of paper (outside), polyethylene, aluminium foil, polyethylene (inside).

Sachet A contains 14.66 g of the electrolyte mix.

Sachet B contains 62.69 g of the glucose.

The veterinary medicinal product is available in cartons of 12 or 48 paired sachets.

Not all pack sizes may be marketed.

#### **5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

### **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Elanco GmbH

### **7. MARKETING AUTHORISATION NUMBERS**

Vm 52127/5068

Vm 52127/3003

### **8. DATE OF FIRST AUTHORISATION**

20 December 1993

### **9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

August 2026

### **10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT**

Veterinary medicinal product not subject to prescription.

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

Approved 18 August 2026

*Gavin Hall*